Merrill has Onyx at neutral

Onyx Pharmaceuticals, Inc. remained at its neutral rating by Merrill Lynch analyst Eric Ende. Merrill expects positive survival data that could allow Sutent to gain a higher market share in firs-line metastatic kidney cancer, resulting in Nexavar gaining a higher second-line share. Phase 3 survival data for Sutent in kidney cancer compared to Interferon-a in front-line, metastatic kidney cancer patients will be presented at ASCO. Median survival analysis could be confounded by the high number of patients crossing over to the treatment arm. Nexavar data in melanoma and liver cancer may be available by the end of 2006. Shares of the Emeryville, Calif., biopharmaceutical company were up $0.65, or 2.85%, at $23.45 on volume of 1,058,100 shares versus the three-month running average of 687,289 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.